Replies to post #288102 on Avid Bioservices Inc (CDMO)

[cjgaddy]

JakeD/BioBS/etal, I still can't figure out if the AACR'17 Biomarker Abstract revealed at AACR.com yesterday is the same as 12-7-16/IASLC/Vienna or a brand new #3!! Study my next post please and give me the definitive answer please! ;-)

[biopharm]

2. 4-3-17/8am #1651 -
Session: TUMOR MICROENVIRONMENT & CHECKPOINTS

“Targeting Phosphatidylserine in Combination with Adoptive T Cell Transfer Eliminates Advanced Tumors without Off-Target Toxicities in a Melanoma Preclinical Model” <=NEW(2nd) MSK STUDY$$$

…...$$$See: More on the Significance of the New MSK/Wolchok+PPHM “ACT” study: http://tinyurl.com/h3ylrku

=> Daniel Hirschhorn-Cymerman 1, Sara Sara Schad 1, Sadna Budhu 1, Zhong Hong 1, Xia Yang 1, Hutchins T. Jeff 2, Bruce D. Freimark 2, Michael J. Gray 2, Jedd Wolchok 1, Taha Merghoub [Memorial Sloan Kettering]
1=Memorial Sloan Kettering CC, NYC [ http://www.mskcc.org/research-areas/labs/jedd-wolchok ]
2=Peregrine Pharmaceuticals

There has been lots of talk about Poster #1651 and now we turn to Bruce D. Friemark and Ramon Valencia and a bit of the intangible that mostly goes unseen most times..... so as most know when you want a recommendation letter of some sort from someone, it is acceptable to provide one and the other party will use it if they decide it is worthy enough.... which brings us to two "very recent" recommendations by Steven Worsley and Dr. Bruce Friemark...

I DOUBT, if Ramon Valencia was not able to close the latest deal, that he would be making note of himself such as "...but persevering and able to close deals effectively." ....IF a deal was not recently closed.

Maybe Renegade Roger Lias was telling the truth about updating us shortly.... but we shall see.

Interesting list of collaborations that we publicly see and the timing of the latest history of PS Targeting makes this for interesting times...hopefully not breadcrumb times.

---------------------------------------------

Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer
Article
Full-text available

Article (PDF Available) · January 2018 with 34 Reads
DOI: 10.2147/ITT.S134834

Olivier Belzile
19.23University of Texas Southwestern Medical Center

Xianming Huang

Jian Gong

Jay Carlson

Alan J Schroit
38.69University of Texas Southwestern Medical Center

Rolf A Brekken

47.52University of Texas Southwestern Medical Center

Bruce Freimark
35.32PEREGRINE PHARMACEUTICALS, INC.


Olivier Belzile,1
Xianming Huang,2,3
Jian Gong,2,3
Jay Carlson,2,3
Alan J Schroit,1
Rolf A Brekken,1
Bruce D Freimark2,3

1Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX,

2Department of Preclinical Research,

3Department of Antibody Discovery, Peregrine Pharmaceuticals, Inc., Tustin, CA, USA

Abstract:

Phosphatidylserine (PS) is a negatively charged phospholipid in all eukaryotic cells that is actively sequestered to the inner leaflet of the cell membrane. Exposure of PS on apoptotic cells is a normal physiological process that triggers their rapid removal by phagocytic engulfment under noninflammatory conditions via receptors primarily expressed on immune cells. PS is aberrantly exposed in the tumor microenvironment and contributes to the overall immunosuppressive signals that antagonize the development of local and systemic antitumor immune responses. PS-mediated immunosuppression in the tumor microenvironment is further exacerbated by chemotherapy and radiation treatments that result in increased levels of PS on dying cells and necrotic tissue. Antibodies targeting PS localize to tumors and block PS-mediated immunosuppression. Targeting exposed PS in the tumor microenvironment may be a novel approach to enhance immune responses to cancer. Keywords: immunosuppression, tumor microenvironment, immunotherapy, imaging, phosphatidylserine, bavituximab

https://www.researchgate.net/profile/Bruce_Freimark

----------------------------------------


I wanted to separate this out, so after one accesses the site above and reads the entire full text..... we can see the collaborators with PS Targeting

---------------------------------------

Top co-authors

Van Nguyen
University of Melbourne

Rolf A Brekken
University of Texas Southwestern Medical Center

Matthew Peacock
Boston University

Stephen W Wright
Pfizer

Deepa Deshpande
universal regulatory inc

Dan Ye
Xi'an Eurasia University

Raviraj Pillai
Dr. Reddy's Laboratories

Michaela Shuler Hatch
University of California, Irvine

Cyril Empig
PEREGRINE PHARMACEUTICALS, INC.

Alain Rolland
Vical

Flavia Pernasetti
Pfizer

Karel Petrak

Sushil Kumar
Dana-Farber Cancer Institute

Taha Merghoub
Memorial Sloan Kettering Cancer Center

Patrick Alexander Baeuerle
Amgen

Takuya Osada
Duke University

Sadna Budhu
Memorial Sloan Kettering Cancer Center

Seth Fisher
Cytovance Biologics

Canan Kasikara
Rutgers New Jersey Medical School

Kyle Schlunegger

Ke Geng
Rutgers New Jersey Medical School

Jeff Hutchins
Not yet on ResearchGate

Jian Gong
Not yet on ResearchGate

Xianming Huang
Not yet on ResearchGate

Michael J. Gray
Not yet on ResearchGate

Christopher C.W. Hughes
Not yet on ResearchGate

Michael Gray
Not yet on ResearchGate

Paul Blezinger
Not yet on ResearchGate

Michael A. Pratta
Not yet on ResearchGate

Connie Chang
Not yet on ResearchGate

Christopher Hughes
Not yet on ResearchGate

Shen Yin
Not yet on ResearchGate

Chris Hughes
Not yet on ResearchGate

Alan J Schroit
Not yet on ResearchGate

John V. Giannaras
Not yet on ResearchGate

Joseph J. Petraitis
Not yet on ResearchGate

Wendi S. Feeser
Not yet on ResearchGate

Dennis Van Epps
Not yet on ResearchGate

Derek Clark
Not yet on ResearchGate

Douglas G. Batt
Not yet on ResearchGate

M Lischwe
Not yet on ResearchGate

Ronald L. Corbett
Not yet on ResearchGate

Susan V. Di Meo
Not yet on ResearchGate

Elizabeth C. Arner
Not yet on ResearchGate

Ronald L. Magolda
Not yet on ResearchGate

Jedd D Wolchok
Not yet on ResearchGate

Patrick Concannon
Not yet on ResearchGate

RI Fox
Not yet on ResearchGate

Sergei V Kotenko
Not yet on ResearchGate

https://www.researchgate.net/profile/Bruce_Freimark

-----------------------------------------------------------


Bruce Freimark, Ph.D.

Research Director | Preclinical Oncology | Immuno-Oncology | Translational Biomarkers

Recommendation given to: Ramon Valencia, MS

Business Development, Licensing & Intellectual Property

January 27, 2018, Bruce worked with Ramon in different groups

Ramon is a highly experienced business development professional with a solid technical background in immuno-oncology and bio-manufacturing. He possesses a strong business sense that makes him extremely effective at dealing with industry professionals at various levels, including senior management at multinational biotech and pharmaceutical corporations involved in immuno-oncology. He is focused, energetic, hard working, and totally reliable. Moreover, you will find Ramon extremely pleasant and tactful, but persevering and able to close deals effectively. He is well organized, a great communicator and meticulous. I trust him and highly recommend him.

https://www.linkedin.com/in/brucefreimark
---------------------------------------------------------
---------------------------------------------------------


Ramon Valencia, MS

Business Development, Licensing & Intellectual Property
Peregrine Pharmaceuticals University of Oxford

...
...

Experience

Peregrine Pharmaceuticals
Director, Business Development & Licensing (Peregrine title: Sr. Manager, BD)
Company Name Peregrine Pharmaceuticals
Dates Employed 2010 – Present Employment Duration 8 yrs
Location Tustin, CA

ACCOMPLISHMENTS:

• Instrumental in establishing a relationship with Dr. Jedd Wolchock and colleagues at MSKCC that led to a research and multiple clinical collaborations in Immunotherapy to validate Peregrine PS targeting immune modulator and identify and develop new targets for immunotherapy.

• Initiated and finalized Immuno-oncology research collaborations with F-Star, Inovio Pharmaceuticals and Pharmacyclics/AbbVie
...
...


Recommendation from Steve Worsley to Ramon Valencia:

Stephen Worsley

Sr. Vice President of Business Development at IndiMolecular

January 29, 2018, Stephen managed Ramon directly

Ramon is a highly experienced business development professional with proven expertise in penetrating large pharma and forming alliances with KOLs in the industry. He has a solid technical background in immune-oncology and bio-manufacturing with a strong business sense that makes him extremely effective at dealing with industry professionals at various levels including senior management at multinational pharmaceutical corporations.

Ramon has significant transaction expertise and prowess; able to move clients beyond formative discussions and into fruitful contract negotiations. Time and time again he proved to be the "Star" of my team who consistently delivered high-value collaborations.

He is very reliable, focused, energetic and hard working. Moreover, you will find Ramon extremely pleasant and tactful, but persevering and able to close deals effectively. He is well organized, a great communicator and meticulous. I trust him and highly recommend him.

Stephen Worsley
Sr. VP Corporate Development
Indimolecular
formerly VP of BD at Peregrine Pharmaceuticals & Avid Bioservices

---------------------------------

Recommendation from Dr. Bruce D. Friemark to Ramon Valencia:

Bruce Freimark, Ph.D.

Research Director | Preclinical Oncology | Immuno-Oncology | Translational Biomarkers

January 27, 2018, Bruce worked with Ramon in different groups

Ramon is a highly experienced business development professional with a solid technical background in immuno-oncology and bio-manufacturing. He possesses a strong business sense that makes him extremely effective at dealing with industry professionals at various levels, including senior management at multinational biotech and pharmaceutical corporations involved in immuno-oncology. He is focused, energetic, hard working, and totally reliable. Moreover, you will find Ramon extremely pleasant and tactful, but persevering and able to close deals effectively. He is well organized, a great communicator and meticulous. I trust him and highly recommend him.

....
...
https://www.linkedin.com/in/ramon-valencia-ms-38501a9

--------------------------------------------------------------

.... the bonus nugget:



Paul Blezinger

Preclinical R&D Specialist
Pharmaceutical consulting Texas A&M University

Experience

Pharmaceutical consulting
Preclinical R&D Specialist
Company Name Pharmaceutical consulting
Dates Employed 2010 – Present Employment Duration 8 yrs
Location Houston area

I am currently conducting in vivo work (preclinical, R&D, tox) for IND approval in the area of CNS, cancer, obesity, and pain modulation.

https://www.linkedin.com/in/paul-blezinger-48a22a4

...... much more bonus nuggets out of all the collaborations but will have to save some for tomorrow : )